These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11824699)

  • 1. Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
    Ott J
    J Psychoactive Drugs; 2001; 33(4):403-7. PubMed ID: 11824699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine.
    Ott J
    J Psychoactive Drugs; 2001; 33(3):273-81. PubMed ID: 11718320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmahuasca: human pharmacology of oral DMT plus harmine.
    Ott J
    J Psychoactive Drugs; 1999; 31(2):171-7. PubMed ID: 10438001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
    Shen HW; Wu C; Jiang XL; Yu AM
    Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
    Halberstadt AL
    Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
    Halberstadt AL; Buell MR; Masten VL; Risbrough VB; Geyer MA
    Psychopharmacology (Berl); 2008 Nov; 201(1):55-66. PubMed ID: 18604652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
    Shen HW; Jiang XL; Winter JC; Yu AM
    Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
    Jiang XL; Shen HW; Yu AM
    Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
    Jiang XL; Shen HW; Yu AM
    Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
    Halberstadt AL; Nichols DE; Geyer MA
    Psychopharmacology (Berl); 2012 Jun; 221(4):709-18. PubMed ID: 22222861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
    McKenna DJ; Towers GH; Abbott F
    J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens.
    McKenna DJ; Towers GH; Abbott FS
    J Ethnopharmacol; 1984 Nov; 12(2):179-211. PubMed ID: 6521493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
    Jiang XL; Shen HW; Mager DE; Yu AM
    Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
    Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
    Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
    Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
    Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
    Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
    J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
    Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
    Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment.
    Brierley DI; Davidson C
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):263-72. PubMed ID: 22691716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela.
    Rodd R
    J Psychoactive Drugs; 2008 Sep; 40(3):301-7. PubMed ID: 19004422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
    Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
    J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.